Wall Street Zen Upgrades Cabot (NYSE:CBT) to Buy

Cabot (NYSE:CBT) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Sunday, Wall Street Zen reports.

CBT has been the topic of a number of other research reports. Truist Financial set a $100.00 target price on Cabot in a research report on Wednesday, August 5th. UBS Group lowered their price target on Cabot from $92.00 to $86.00 and set a “neutral” rating for the company in a research report on Monday, October 5th. Mizuho raised their price target on Cabot from $80.00 to $90.00 and gave the stock a “neutral” rating in a research report on Thursday, June 25th. JPMorgan Chase & Co. lifted their price objective on Cabot from $70.00 to $78.00 and gave the company an “underweight” rating in a research note on Friday, August 7th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Cabot in a report on Friday, August 21st. Two analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $87.80.

Cabot Stock Down 0.8%

Shares of CBT opened at $74.33 on Friday. The firm has a market cap of $3.84 billion, a P/E ratio of 20.94, a price-to-earnings-growth ratio of 8.82 and a beta of 0.83. Cabot has a 12-month low of $58.33 and a 12-month high of $94.53. The company’s 50-day moving average price is $81.16 and its 200 day moving average price is $82.51. The company has a current ratio of 1.47, a quick ratio of 0.97 and a debt-to-equity ratio of 0.48.

Cabot (NYSE:CBT) last posted its earnings results on Monday, August 3rd. The specialty chemicals company reported $1.67 EPS for the quarter, beating analysts’ consensus estimates of $1.66 by $0.01. Cabot had a net margin of 5.23% and a return on equity of 20.29%. The company had revenue of $982.00 million for the quarter, compared to analysts’ expectations of $943.16 million. During the same quarter in the prior year, the company posted $1.90 earnings per share. Cabot’s revenue for the quarter was up 6.4% compared to the same quarter last year. Cabot has set its FY 2026 guidance at 6.150-6.450 EPS. On average, sell-side analysts forecast that Cabot will post 6.35 earnings per share for the current year.

Insider Buying and Selling at Cabot

In related news, CEO Sean Keohane sold 134,895 shares of the company’s stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $85.00, for a total transaction of $11,466,075.00. Following the sale, the chief executive officer directly owned 404,134 shares of the company’s stock, valued at $34,351,390. This represents a 25.03% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 229,597 shares of company stock valued at $19,646,746 in the last ninety days. Insiders own 3.08% of the company’s stock.

Hedge Funds Weigh In On Cabot

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Cabot during the 2nd quarter worth about $33,000. Caitong International Asset Management Co. Ltd raised its position in shares of Cabot by 76.8% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 944 shares of the specialty chemicals company’s stock worth $63,000 after acquiring an additional 410 shares in the last quarter. Rockefeller Capital Management L.P. lifted its stake in Cabot by 115.3% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,152 shares of the specialty chemicals company’s stock worth $76,000 after purchasing an additional 617 shares during the last quarter. Global Retirement Partners LLC purchased a new stake in Cabot during the second quarter worth approximately $88,000. Finally, Parallel Advisors LLC lifted its stake in Cabot by 10.5% during the first quarter. Parallel Advisors LLC now owns 1,843 shares of the specialty chemicals company’s stock worth $139,000 after purchasing an additional 175 shares during the last quarter. Hedge funds and other institutional investors own 93.18% of the company’s stock.

Cabot Company Profile

Cabot Corporation (NYSE: CBT) is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts. Founded in 1882 by Godfrey Lowell Cabot, the company develops and manufactures materials used by industrial and consumer-product manufacturers worldwide.

Cabot’s products include reinforcing carbon blacks used in tires, automotive components, and other rubber products; specialty carbon blacks used in coatings, plastics, inks, and batteries; and fumed silica used in adhesives, sealants, coatings, and personal-care applications.